Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.

The USA’s Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's ...

Lecta has expanded its range of metallized papers with Metalvac Ice Cream, a paper said to meet the current technical ...

Dermot Kenny, who leads STEM and Research Partnership within Inizio Advisory, shares his journey from bench scientist to CEO, ...

The report showed that 89 per cent of confirmed Lassa fever cases in 2025 came from four states: Ondo 36 per cent, Edo 24 per ...